Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tests Of Nanosilver-Based Consumer Products Needed To Define Risks – PEN

This article was originally published in The Tan Sheet

Executive Summary

Widespread use in toothpaste and other consumer products of nanosilver - one of the most toxic metals to aquatic organisms - highlights the need for research to better manage the ingredient's environmental and human health risks, according to a new report from the Project on Emerging Nanotechnologies

You may also be interested in...



EPA Would Regulate Nano Materials Under Research Project’s Proposal

A report commissioned by the Project on Emerging Nanotechnologies proposes a five-year strategy lawmakers and the Environmental Protection Agency, among others, can follow to create an "intelligent" approach to nanotechnology oversight

Honest Company IPO Raises $413M, Questions About Valuation

Jessica Alba’s baby has grown into a US personal-care and home-goods market where natural, clean and ethical positioning has become commonplace. Investors will be watching to see if Honest can overcome challenges noted in its IPO prospectus, including competitive pressures, limited retail shelf space, and obstacles to international expansion.

ACI’s Antiseptic Testing Continues Under Specter Of FDA Administrative Order

The American Cleaning Institute is preparing to submit a healthcare personnel hand wash study to the US FDA pending confidentiality discussions, along with results from a literature review on the topic of antimicrobial resistance. A progress report is due to the agency in October, which could stave off an administrative order under the reformed OTC drug review system.

Topics

UsernamePublicRestriction

Register

PS102131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel